 |
|
Lung Cancer Trial Results
6. Longer Course of Radiation Provides Better Palliation in Advanced NSCLC
(Posted: 01/30/2007) - In patients with advanced non-small cell lung cancer and a poor outlook, a longer, less intense course of radiation treatment improved patients' life expectancy and was cost-effective, according to the Dec. 20, 2006, Journal of the National Cancer Institute.
7. ERCC1 Expression in Lung Cancer May Predict Survival Benefit from Cisplatin
(Posted: 09/20/2006) - A substudy from the International Adjuvant Lung Cancer Trial (IALT) - the IALT Bio study - has identified lack of expression of the DNA-repair protein ERCC1 as a possible predictor of increased survival after cisplatin-based chemotherapy, according to the Sept. 7, 2006, issue of the New England Journal of Medicine.
8. Erlotinib (Tarceva®) Extends Survival in Advanced Lung Cancer
(Posted: 06/05/2004, Updated: 08/30/2006) - Erlotinib (Tarceva®) prolonged survival in patients with advanced non-small cell lung cancer who had progressed after standard chemotherapy, according to findings reported at the 2004 ASCO meeting in New Orleans.
9. Whole Brain Radiation May be Postponed in Cancer Patients with Limited Metastasis to the Brain
(Posted: 08/28/2006) - Whole brain radiation therapy can be delayed without compromising survival in patients with four or fewer contained metastases to the brain, according to the June 7, 2006, issue of the Journal of the American Medical Association.
10. Cisplatin-Based Chemotherapy Improves Survival in Non-Small Cell Lung Cancer
(Posted: 06/04/2006) - Combined data from five large randomized clinical trials confirmed that cisplatin-based chemotherapy extends survival for patients with stage II or stage III non-small cell lung cancer, according to findings presented at the 2006 meeting of the American Society of Clinical Oncology.
< Previous 1 2 3 4 5 Next >
|
|
|
